Business
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
About this update from Vyome Holdings, Inc.
[{"type":"text","content":"\n\nVyome has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market1\n\n\n\nVT-1953 regulatory submissions to the FDA for Orphan Drug Designation status and proposals for constructive FDA guidance on the next steps of development\n\n\n\nCompany ends Q1 2026 with approximately $8.8 million in cash and cash equivalents while maintaining a clean capital structure with no debt, no preferred stock, and no toxic financing instruments\n\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nVyome Holdings, Inc. (Nasdaq: HIND)(“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update.\n\n\nKrishna Gupta, Chairman of Vyome, said, “Over the last several quarters, Vyome has executed with focus and discipline, advancing differentiated programs in areas of significant unmet medical need focused on inflammatory disorders. Inflammation remains one of the world’s largest problems, and we believe Vyome is well positioned for long-term value creation. We continue to strengthen our scientific, operational, and governance foundation while remaining highly disciplined on capital structure and shareholder alignment.”\n\n\nVenkat Nelabhotla, CEO of Vyome, stated, “We continue to advance VT-1953 toward pivotal-stage readiness while maintaining a strong focus on disciplined execution, regulatory engagement, manufacturing preparedness, and financial stewardship. We submitted to the FDA an application for the approval of orphan drug designation status and proposals across several areas of the next stages of development readiness, and continue to believe VT-1953 addresses a major unmet need in malignant fungating wounds, where there are currently no FDA-approved therapies specifically addressing the condition.”\n\n\n“Importantly, we have continued to preserve what we believe is one of the Company’s key differentiators: a clean and disciplined capital structure with no debt, no preferred stock, and no toxic financing instruments. We remain focused on creating long-term shareholder value while advancing our immuno-inflammatory and rare disease strategy,” concluded Mr. Nelabhotla.\n\n\n...